VERTEX PHARMACEUTICALS INCORPORATED |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 396 USD | -0.33% |
|
-2.11% | -2.69% |
| Apr. 12 | North American Morning Briefing : Big Banks Kick -2- | DJ |
| Apr. 11 | Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech | MT |
Cet article est réservé aux membres
Déjà membre ?
Log InPas encore membre ?
Inscription Gratuite
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
397.4
USD
Average target price
461.3
USD
Spread / Average Target
+16.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.69% | 103B | |
| +1.89% | 96.56B | |
| +1.92% | 22.61B | |
| -18.03% | 21.18B | |
| -4.50% | 19.07B | |
| -41.75% | 16.53B | |
| -24.38% | 14.46B | |
| +2.13% | 13.25B | |
| +21.70% | 11.1B | |
| -18.43% | 9.41B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Vertex Pharmaceuticals : Truist Securities Adjusts Price Target on Vertex Pharmaceuticals to $331 From $305, Maintains Buy Rating
